Percutaneous image-guided cryoablation in inoperable extra-abdominal desmoid tumors: a study of tolerability and efficacy.

Cardiovasc Intervent Radiol

Department of Radiology, Hôpital Pellegrin, CHU de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France.

Published: December 2014

Objective: To determine the tolerability, effectiveness and outcomes of percutaneous image-guided cryoablation on inoperable extra-abdominal desmoid tumors.

Methods: Between 2011 and 2012, 13 patients (mean age 39.3 years, range 15-74) with inoperable extra-abdominal desmoid tumors were consecutively treated with cryoablation (17 tumors treated in 17 procedures), including two patients with Gardner syndrome and nine recurrences after surgery. Disease-free survival (DFS) and local control based on RECIST criteria were calculated on prospective clinical and imaging follow-up until 2013.

Results: Cryoablation was performed under ultrasound (n = 8), computed tomography (n = 1), or combined (n = 8) guidance, and under general (n = 15) or local (n = 2) anesthesia. A major complication was observed in one session (5.8%). Mean follow-up was 11.3 months (6-27 months). Among all the patients treated, eight patients (47%) presented residual tumors on the first magnetic resonance follow-up, which were asymptomatic. The DFS rate was stable at 82.3% (95% confidence interval 0.55-0.94) at 6, 12, and 24 months. The local tumor progression rate was 0% at 6, 12, and 24 months. Two patients (12%) presented an in situ recurrence.

Conclusions: Despite high rates of partial ablation, percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with inoperable extra-abdominal desmoid tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-013-0830-9DOI Listing

Publication Analysis

Top Keywords

inoperable extra-abdominal
16
extra-abdominal desmoid
16
percutaneous image-guided
12
image-guided cryoablation
12
desmoid tumors
12
cryoablation inoperable
8
local control
8
months patients
8
patients
6
cryoablation
5

Similar Publications

The cornerstone of ovarian cancer treatment is complete surgical cytoreduction. The gold-standard option in the absence of extra-abdominal metastases and intra-abdominal inoperable circumstances is primary cytoreductive surgery (CRS). However, achieving complete cytoreduction is challenging, and only possible in a selected patient population.

View Article and Find Full Text PDF

Initial treatment for surgery-naïve desmoid tumors by high intensity focused ultrasound.

Front Oncol

July 2024

Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Introduction: Desmoid tumor (DT) is a rare proliferative disease occurring in connective tissues, characterized by high infiltration and recurrence rates. While surgery remains the primary treatment, its recurrence risk is high, and some extra-abdominal desmoid tumors are inoperable due to their locations. Despite attempts with radiotherapy and systemic therapy, the efficacy remains limited.

View Article and Find Full Text PDF

Complex surgery is an essential component in the management of advanced ovarian cancer. Furthermore, achieving complete gross resection in cytoreductive surgery appears to be associated with significant survival benefits in patients with advanced ovarian cancer. The goal of this review is to demonstrate the advancement of surgical techniques in gynecologic oncology surgery, including resection of disease within the intrathoracic and inguinal regions.

View Article and Find Full Text PDF

Fibromatosis with aggressive demeanor: Benign impersonator of malignancy.

World J Nucl Med

December 2020

Department of Nuclear Medicine and PET CT, Apollo Hospitals, Chennai, Tamil Nadu, India.

Fibromatosis or desmoid fibromatosis is a rare benign neoplasm and develops commonly in the abdominal wall, abdominal cavity, or extra-abdominal sites. The mainstay of treatment is surgery. Chemotherapy and radiotherapy are preferred in cases of inoperable/relapse or a multifocal disease.

View Article and Find Full Text PDF

Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option.

J Cancer Res Ther

November 2020

Department of Medical Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.

Objective: Aggressive fibromatosis (AF), also called desmoid tumor, is an uncommon soft-tissue neoplasm. Characteristically, it expands locally without metastatic potential. However, its tendency of relapse after curative resections has been well documented.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!